1. : Ander Regueiro1,5, MD; Ricard Tresserras2, MD; Javier Goicolea3,5, MD; Antonio Fernndez-Ortiz45, MD, PhD; Carlos Macaya4,5, MD, PhD; Manel Sabat1,5*, MD, PhD 1. , , , , , (Cardiology Department, Thorax Institute, Hospital Clnic, University of Barcelona, Barcelona, Spain); 2. , , , (Deputy Director for Health Planning, Department of Health, Autonomous Government of Catalonia, Spain); 3. , Puerta de Hierro, , , ( Interventional Cardiology Department, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain);4. San Carlos, , (Hospital Clnico San Carlos, Madrid, Spain); 5. Stent for Life, (Steering Committee, Stent for Life Initiative, Spain) * : , , (Cardiology Department, Thorax Institute, Hospital Clinic, Villarroel 170, ES-08036 Barcelona, Spain). E-mail: masabate@clinic.ub.es ST (ST), ST. 17 . 2002 ., ST, , 39% . . ST, ST. , , , . ST (ST). () , IA (European Society of Cardiology guidelines) (1). ST , , ST. ST (2). , ST, , (3). ST, , , .

2. ST 17 . . 2002 . ST. , ST, . , Stent for Life (Stentfor Life Spain), , ST, 39% . ST , , . (National Institute of Statistics)(4) 2010 . 59165 19437 ( ). 38% ST (5). ST 44 100000 . , (Marrugat , ) 70 ST 100000 . , ST , . (Interventional Cardiology Working Group of the Spanish Society ofCardiology) 64331 2010 ., 14248 (22,1%) ST, 10339 (72,6%) . , 2010 . 219 ( 1). , ST (158,98 324,12, p